<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a phase 2 study, 23 patients with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> with <z:mpath ids='MPATH_173'>myeloid metaplasia</z:mpath> were treated with <z:chebi fb="0" ids="31690">imatinib mesylate</z:chebi> at a constant dose of 400 mg/d </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment was held in 16 patients (70%), after 1 to 12 weeks, because of side effects (<z:hpo ids='HP_0001875'>neutropenia</z:hpo>, 6 patients; musculoskeletal pain, 5 patients; <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo>, 4 patients; <z:hpo ids='HP_0000969'>edema</z:hpo>, 3 patients; <z:hpo ids='HP_0002014'>diarrhea</z:hpo> and <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, 1 patient) </plain></SENT>
<SENT sid="2" pm="."><plain>Including patients in whom retreatment at a reduced dose was possible, 11 patients (48%) were able to continue treatment beyond 3 months </plain></SENT>
<SENT sid="3" pm="."><plain>None of the patients experienced a response in <z:hpo ids='HP_0001903'>anemia</z:hpo>, and only 2 had partial responses in <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A greater than 50% increase in platelet count was documented in 11 (48%) patients, but not in those with baseline platelet counts of less than 100 x 10(9)/L </plain></SENT>
<SENT sid="5" pm="."><plain>In vitro, <z:chebi fb="0" ids="31690">imatinib mesylate</z:chebi> caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit </plain></SENT>
</text></document>